Wednesday, June 07, 2006 7:24:47 AM
In addition to that:
3.3 Proof of Infringement and Damages
Proof of infringement and of the quantum of damages is relatively simple in U.S.IP litigation. Once an IP rights owner has sufficient evidence to have a good faith belief that someone is infringing, satisfying Rule 11 of the Federal Rules of Civil Procedure, an infringement case can be filed. Then, discovery can be taken, using the power of the court to require oral and written responses, and production of documents and things. As a practical matter, the limit on discovery is whether the requests are “reasonably calculated to lead to the discovery of admissible evidence.”[13] The U.S. courts may issue protective orders to limit discovery and to control the use of information produced in discovery. Trade secrets and other confidential information must be produced, but its circulation and use can be limited by court order.[14]
http://www.fr.com/news/articledetail.cfm?articleid=67#_ftnref14
As I understand it now, DNA is basically asking for more production information from INSM; which was NOT revealed during the hearing and which may be of 'any interest' to DNA...in order to specify in detail what INSM, presumably, is infringing.
A.
3.3 Proof of Infringement and Damages
Proof of infringement and of the quantum of damages is relatively simple in U.S.IP litigation. Once an IP rights owner has sufficient evidence to have a good faith belief that someone is infringing, satisfying Rule 11 of the Federal Rules of Civil Procedure, an infringement case can be filed. Then, discovery can be taken, using the power of the court to require oral and written responses, and production of documents and things. As a practical matter, the limit on discovery is whether the requests are “reasonably calculated to lead to the discovery of admissible evidence.”[13] The U.S. courts may issue protective orders to limit discovery and to control the use of information produced in discovery. Trade secrets and other confidential information must be produced, but its circulation and use can be limited by court order.[14]
http://www.fr.com/news/articledetail.cfm?articleid=67#_ftnref14
As I understand it now, DNA is basically asking for more production information from INSM; which was NOT revealed during the hearing and which may be of 'any interest' to DNA...in order to specify in detail what INSM, presumably, is infringing.
A.
Recent INSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:41:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:01:21 PM
- Insmed Provides Clinical Update on Phase 2b CEDAR Study • PR Newswire (US) • 04/07/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:42:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:07:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 09:10:46 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/01/2026 08:03:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:02:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:13:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/30/2026 09:31:03 PM
- Insmed shares rise after UTHR trial data and Morgan Stanley upgrade • IH Market News • 03/30/2026 03:04:13 PM
- Insmed shares rise on positive results from ARIKAYCE Phase 3b study • IH Market News • 03/23/2026 02:34:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:30 AM
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease • PR Newswire (US) • 03/23/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:05:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 08:57:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:59:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:16:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:15:10 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:14:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:04:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:04:19 PM
